How much does Oxford Gene Technology (Operations) Ltd make?

Oxford Gene Technology (Operations) Ltd reported revenue of £10.3m and a loss of £353k in the year to 31 Mar 2025, according to its accounts filed at Companies House.

How many employees does Oxford Gene Technology (Operations) Ltd have?

Oxford Gene Technology (Operations) Ltd reported an average of 58 employees in the year to 31 Mar 2025.

Is Oxford Gene Technology (Operations) Ltd profitable?

No — Oxford Gene Technology (Operations) Ltd reported a loss of £353k in the year to 31 Mar 2025.

Company No. 03845432 · Incorporated 21 Sep 1999

Oxford Gene Technology (Operations) Ltd

Registered name: OXFORD GENE TECHNOLOGY (OPERATIONS) LTD

Part of Sysmex Corporation group

Oxford Gene Technology (Operations) Ltd made £10.3m revenue and a £353k loss in the year to 31 Mar 2025.

Oxford Gene Technology (Operations) Ltd’s revenue fell 10% to £10.3m in the year to 31 Mar 2025, with a loss of £353k and 58 employees. The company is classified under “research and experimental development on biotechnology” and is based in Kidlington; we hold 4 years of its filed accounts.

Full P&L filedSection M · Professional, scientific and technical activitiesSIC 72110Research and experimental development on biotechnology

Status: Active
Location: Kidlington, South East
Age: 27 yrs · since 1999
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The Company's immediate controlling party is Oxford Gene Technology IP Limited, incorporated in England & Wales. In the opinion of the directors, the Company's ultimate parent Company and ultimate con”

Latest accounts · year to 31 Mar 2025

Key figures

Revenue

£10.3m

Growth ▼10.4%

Profit

−£353k

Growth ▼146.5%

Profit margin

−3.4%

Gross 43.9%

Employees

Change ▲20.8%

Profit / employee

−£6.1k

Revenue/employee £178k

Profitable streak

0yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

4 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Mar 2022	31 Mar 2023	31 Mar 2024	31 Mar 2025
Disclosure	Full P&L	Full P&L	Full P&L	Full P&L
Profit & loss
Revenue (turnover)	£11.2m	£10.8m	£11.6m	£10.3m
Cost of sales	£6.7m	£6m	£6.1m	£5.8m
Gross profit	£4.5m	£4.8m	£5.4m	£4.5m
Operating profit	£1.3m	£750k	£576k	−£561k
Profit before tax	£1.3m	£994k	£1.1m	−£101k
Profit after tax	£1.3m	£1.1m	£758k	−£353k
Profit (best available)	£1.3m	£1.1m	£758k	−£353k
Staff costs	£3.2m	£3.4m	£3.9m	£4.4m
Employees (average)	45	45	48	58
Ratios
Profit margin	11.6%	9.7%	6.6%	−3.4%
Gross margin	40.3%	44.5%	46.8%	43.9%
Revenue per employee	£249k	£241k	£241k	£178k
Profit per employee	£28.8k	£23.3k	£15.8k	−£6.1k
Growth (year on year)
Revenue growth	—	▼3.3%	▲6.6%	▼10.4%
Profit growth	—	▼18.9%	▼27.8%	▼146.5%
Headcount growth	—	0%	▲6.7%	▲20.8%
Balance sheet — indirect signals, not revenue
Cash at bank	£11m	£6.1m	£5.1m	£4.2m
Net assets	−£27.8m	−£26.7m	−£25.9m	−£26.3m
Fixed assets	£180k	£163k	£3.2m	£3.1m
Current assets	£26.4m	£32.1m	£35.3m	£39.9m
Debtors	£729k	£1.1m	£1.8m	£984k
Deferred income	£350k	£359k	£544k	£696k
Source	Accounts · bulk data Dec 2023	Accounts · bulk data Dec 2023	FullAccounts · bulk data Dec 2024	FullAccounts · bulk data Dec 2025

Derived from the latest filing

How the business works

Profit margin: −3.4%; Profit ÷ revenue.
Gross margin: 43.9%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £178k; Revenue ÷ average employees.
Profit per employee: −£6.1k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 29.9%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 6.7%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 9.5%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: —; Now −£26.3m
Cash at bank: ▼17%; Now £4.2m
Headcount: ▲21%; Now 58
Deferred income: ▲28%; Now £696k
Fixed assets: ▼5%; Now £3.1m

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Sysmex Corporation (registered outside the UK register)ultimate parent75–100%
Oxford Gene Technology IP Limited75–100%
Oxford Gene Technology (Operations) Ltdthis company

Bands show the share of ownership each company holds in the one below it.

Sister companies (3)

Cytocell LimitedRev. £15.5m · Profit £3.4m
Oxford Gene Technology (Southern) LimitedRev. — · Profit −£581
Oxford Gene Technology LimitedFigures not disclosed

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Mar 2025 (profit −£353k), from the Companies House accounts bulk data published Dec 2025. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.